{"filing":{"accession_number":"0000879407-26-000050","cik":"0000879407","ticker":"ARWR","company_name":"ARROWHEAD PHARMACEUTICALS, INC.","form":"8-K","filing_date":"2026-06-16","report_date":null,"primary_document":"arwr-20260612.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/879407/000087940726000050/arwr-20260612.htm"},"events":[{"id":11285,"run_id":9903,"accession_number":"0000879407-26-000050","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The filing discloses the appointment of Dr. Matt Cohen as a director of Arrowhead Pharmaceuticals effective June 12, 2026. While the disclosure includes compensatory details (a sign-on grant of restricted stock units valued at $887,000), the principal action is the appointment itself. The extensive background information on Dr. Cohen's 25+ years of healthcare investing experience and his roles at major institutions (JP Morgan, Vida Ventures) underscores the materiality of adding a qualified director to the board.","company_name":"ARROWHEAD PHARMACEUTICALS, INC.","ticker":"ARWR","filing_date":"2026-06-16","form":"8-K","submitted_at":null,"items":[{"id":7837,"accession_number":"0000879407-26-000050","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Dr. Matt Cohen as a director of Arrowhead Pharmaceuticals effective June 12, 2026. While the disclosure includes compensatory details (a sign-on grant of restricted stock units valued at $887,000), the principal action is the appointment itself. The extensive background information on Dr. Cohen's 25+ years of healthcare investing experience and his roles at major institutions (JP Morgan, Vida Ventures) underscores the materiality of adding a qualified director to the board.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-16T20:04:05.790049+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":7837,"accession_number":"0000879407-26-000050","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Dr. Matt Cohen as a director of Arrowhead Pharmaceuticals effective June 12, 2026. While the disclosure includes compensatory details (a sign-on grant of restricted stock units valued at $887,000), the principal action is the appointment itself. The extensive background information on Dr. Cohen's 25+ years of healthcare investing experience and his roles at major institutions (JP Morgan, Vida Ventures) underscores the materiality of adding a qualified director to the board.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-16T20:04:05.790049+00:00","company_name":"ARROWHEAD PHARMACEUTICALS, INC.","ticker":"ARWR","filing_date":"2026-06-16"}]}